CLVSF (CellaVision AB) ROCE % : 18.98% (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is CellaVision AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CellaVision AB's annualized ROCE % for the quarter that ended in Sep. 2024 was 18.98%.

CellaVision AB ROCE % Historical Data

The historical data trend for CellaVision AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB ROCE % Chart

CellaVision AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

31.49

22.48

24.57

19.49

21.48

CellaVision AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															17.22	31.25	19.35	24.07	18.98

CellaVision AB ROCE % Calculation

CellaVision AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	16.328	/	( ( (85.927 - 12.824)	+	(90.539 - 11.616) )	/ 2 )
	=	16.328	/	( (73.103	+	78.923)	/ 2 )
	=	16.328	/	76.013
	=	21.48 %

CellaVision AB's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	15.444	/	( ( (91.285 - 12.107)	+	(96.181 - 12.65) )	/ 2 )
	=	15.444	/	( ( 79.178	+	83.531 )	/ 2 )
	=	15.444	/	81.3545
	=	18.98 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

CellaVision AB (OTCPK:CLVSF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CellaVision AB ROCE % Related Terms

Thank you for viewing the detailed overview of CellaVision AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CellaVision AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (OTCPK:CLVSF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CEVI:Sweden 0MR5:UK C26:Germany

Address

Mobilvagen 12, Lund, SWE, 22362

Website

https://www.cellavision.com

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers/software.